読み込み中
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
最新データ
HK$7.355
−HK$0.185 · -2.45%
日中の時刻はHKTです。市場データは遅延する場合があります。
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
日中レンジ
現在 HK$7.355
52週レンジ
現在 HK$7.355
日中の時刻はHKTです。市場データは遅延する場合があります。
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
日中レンジ
現在 HK$7.355
52週レンジ
現在 HK$7.355
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CNY） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5.52億 CNY | 6.4億 CNY | 2.19億 CNY | 1.67億 CNY | 1.46億 CNY |
| 売上原価 | 1.25億 CNY | 6031.6万 CNY | 5523.7万 CNY | 4420.7万 CNY | 302.8万 CNY |
| 粗利益 | 4.27億 CNY | 5.8億 CNY | 1.64億 CNY | 1.23億 CNY | 1.43億 CNY |
| 研究開発 | 4.94億 CNY | 4.04億 CNY | 4.08億 CNY | 4.68億 CNY | 4.81億 CNY |
| 販売・一般管理 | 8164.97万 CNY | 7510.9万 CNY | 7933.8万 CNY | 8694万 CNY | 7755万 CNY |
| 営業費用 | 5.76億 CNY | 4.79億 CNY | 4.87億 CNY | 5.55億 CNY | 5.59億 CNY |
| 受取利息 | 3438.25万 CNY | 4925.5万 CNY | 7404.2万 CNY | 3386.6万 CNY | 2780.7万 CNY |
| 支払利息 | 725.62万 CNY | 992.4万 CNY | 1217.9万 CNY | 1420.6万 CNY | 1318.2万 CNY |
| 減価償却費と償却費 | 6468.3万 CNY | 7703.1万 CNY | 6911.8万 CNY | 5518.8万 CNY | 4110.2万 CNY |
| 営業利益 | −1.49億 CNY | 1.01億 CNY | −3.06億 CNY | −4.32億 CNY | −4.16億 CNY |
| 純利益 | −1.11億 CNY | 1.66億 CNY | −2.11億 CNY | −3.26億 CNY | −4.12億 CNY |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
